GENE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2188058, encodeId=7d4d21880589b, content=偏重的研究方向：生物信息 经验分享：有点无语，投的生信以没有做验证为理由拒稿，然而无论是标题还是摘要都着重写了验证部分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a38173164, createdName=ms7000001263360888, createdTime=Sun Feb 18 22:49:56 CST 2024, time=2024-02-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187197, encodeId=70ea218e19781, content=一般几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Feb 13 22:26:33 CST 2024, time=2024-02-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2129635, encodeId=778f212963576, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度还可以，没有那么慢。 2.4，投稿 2.17, 送外审 3.28，大修 4.7，修回 4.26，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0de2443241, createdName=然、, createdTime=Tue May 02 02:14:34 CST 2023, time=2023-05-02, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=909655, encodeId=fe449096558c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：基因 经验分享：刚发表了一篇，我也来分享一下：纯生信分析文章，Received 28 July 2020; Received in revised form 1 November 2020; Accepted 1 December 2020；Available online 14 December 2020。审稿偏慢，一审3个月，小修，很快接收，订阅模式不需要版面费，这一点非常好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32432154011, createdName=137EoZs9227, createdTime=Sun Dec 20 22:23:33 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156687, encodeId=2582215668e2e, content=接收之后多久发proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Fri Sep 08 11:03:12 CST 2023, time=2023-09-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1068815, encodeId=a3b61068815a7, content=请问大家推荐审稿人怎么填的，还有通讯作者我咋改不了了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c8f2b10a854a89661cdd74b28f3aab31/5ce6cf574e5eba0e8ed4f71f7dcc1d37.jpg, createdBy=23695158969, createdName=146b113dm12(暂无昵称), createdTime=Wed Nov 10 00:14:59 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239026, encodeId=f721123902632, content=审稿速度:6.0 偏重的研究方向：遗传 经验分享：10.14投稿 10.18Associate Editor 10.29Editor in cheif under review 12.7修稿意见 12.24修后重投 1.15Editor in cheif under review 1.19修稿意见 2.16修后重投 2.25小修意见 2.28修回 3.4接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a66a5585339, createdName=一把辛酸泪, createdTime=Tue Aug 16 14:46:10 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586729, encodeId=5430586e294a, content=纯生信分析，没做基础实验验证，有可能收吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/01/253ec4d94f720dd8d7ff9fd9eee11139.jpg, createdBy=75232378321, createdName=烽火很忙, createdTime=Mon Mar 16 00:00:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228064, encodeId=08051228064f1, content=偏重的研究方向：分子生物学 经验分享：好垃圾的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0f35577132, createdName=机智二次元, createdTime=Wed Jun 22 20:27:06 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237318, encodeId=eca9123e3183d, content=虽说是一个老牌的期刊，但是找的审稿人非常不专业。 我投的方向是纯基础研究，内容是XBP1s对增殖及成骨相关的调控作用。送审以后一个月返回意见，一共两个审稿人，其中第一个（感觉是非英语国家的人）首先质疑了我qPCR的扩增效率，然后让我提供提取的RNA的浓度；还提了一个问题是“明明那么多促进增殖和成骨的基因，为什么作者一定要聚焦于XBP1s”，我真的是气不打一处来，introduction和亮点明明写得很清楚，我就是研究ERS通路的你问我为啥要研究这个？那我问你为啥要每天吃饭你怎么说？ 明明都是用试剂盒提取的流程化的东西非要质疑一遍，我就又给他跑了一边RNA电泳，一共十几个问题我都给他加了数据图，并且补了染色实验，疫情封控下还忙活了一个多月，补的实验数据几乎是原稿的一倍，都够再写一篇的了，结果返回去不到一天就光速审完，一周后编辑拒稿，也没有具体理由，也没有拒稿意见。找的这个审稿人真的恶心到我了，也不说文章缺陷在哪里，就是为了拒稿而拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56466500170, createdName=ms5000001139229179, createdTime=Mon Aug 08 12:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2024-02-18 ms7000001263360888 来自广东省

偏重的研究方向：生物信息
经验分享：有点无语，投的生信以没有做验证为理由拒稿，然而无论是标题还是摘要都着重写了验证部分

16 0

[GetPortalCommentsPageByObjectIdResponse(id=2188058, encodeId=7d4d21880589b, content=偏重的研究方向：生物信息 经验分享：有点无语，投的生信以没有做验证为理由拒稿，然而无论是标题还是摘要都着重写了验证部分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a38173164, createdName=ms7000001263360888, createdTime=Sun Feb 18 22:49:56 CST 2024, time=2024-02-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187197, encodeId=70ea218e19781, content=一般几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Feb 13 22:26:33 CST 2024, time=2024-02-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2129635, encodeId=778f212963576, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度还可以，没有那么慢。 2.4，投稿 2.17, 送外审 3.28，大修 4.7，修回 4.26，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0de2443241, createdName=然、, createdTime=Tue May 02 02:14:34 CST 2023, time=2023-05-02, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=909655, encodeId=fe449096558c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：基因 经验分享：刚发表了一篇，我也来分享一下：纯生信分析文章，Received 28 July 2020; Received in revised form 1 November 2020; Accepted 1 December 2020；Available online 14 December 2020。审稿偏慢，一审3个月，小修，很快接收，订阅模式不需要版面费，这一点非常好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32432154011, createdName=137EoZs9227, createdTime=Sun Dec 20 22:23:33 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156687, encodeId=2582215668e2e, content=接收之后多久发proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Fri Sep 08 11:03:12 CST 2023, time=2023-09-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1068815, encodeId=a3b61068815a7, content=请问大家推荐审稿人怎么填的，还有通讯作者我咋改不了了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c8f2b10a854a89661cdd74b28f3aab31/5ce6cf574e5eba0e8ed4f71f7dcc1d37.jpg, createdBy=23695158969, createdName=146b113dm12(暂无昵称), createdTime=Wed Nov 10 00:14:59 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239026, encodeId=f721123902632, content=审稿速度:6.0 偏重的研究方向：遗传 经验分享：10.14投稿 10.18Associate Editor 10.29Editor in cheif under review 12.7修稿意见 12.24修后重投 1.15Editor in cheif under review 1.19修稿意见 2.16修后重投 2.25小修意见 2.28修回 3.4接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a66a5585339, createdName=一把辛酸泪, createdTime=Tue Aug 16 14:46:10 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586729, encodeId=5430586e294a, content=纯生信分析，没做基础实验验证，有可能收吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/01/253ec4d94f720dd8d7ff9fd9eee11139.jpg, createdBy=75232378321, createdName=烽火很忙, createdTime=Mon Mar 16 00:00:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228064, encodeId=08051228064f1, content=偏重的研究方向：分子生物学 经验分享：好垃圾的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0f35577132, createdName=机智二次元, createdTime=Wed Jun 22 20:27:06 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237318, encodeId=eca9123e3183d, content=虽说是一个老牌的期刊，但是找的审稿人非常不专业。 我投的方向是纯基础研究，内容是XBP1s对增殖及成骨相关的调控作用。送审以后一个月返回意见，一共两个审稿人，其中第一个（感觉是非英语国家的人）首先质疑了我qPCR的扩增效率，然后让我提供提取的RNA的浓度；还提了一个问题是“明明那么多促进增殖和成骨的基因，为什么作者一定要聚焦于XBP1s”，我真的是气不打一处来，introduction和亮点明明写得很清楚，我就是研究ERS通路的你问我为啥要研究这个？那我问你为啥要每天吃饭你怎么说？ 明明都是用试剂盒提取的流程化的东西非要质疑一遍，我就又给他跑了一边RNA电泳，一共十几个问题我都给他加了数据图，并且补了染色实验，疫情封控下还忙活了一个多月，补的实验数据几乎是原稿的一倍，都够再写一篇的了，结果返回去不到一天就光速审完，一周后编辑拒稿，也没有具体理由，也没有拒稿意见。找的这个审稿人真的恶心到我了，也不说文章缺陷在哪里，就是为了拒稿而拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56466500170, createdName=ms5000001139229179, createdTime=Mon Aug 08 12:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2024-02-13 国统乃我辈之愿来自海南省

一般几个审稿人？

23 0

[GetPortalCommentsPageByObjectIdResponse(id=2188058, encodeId=7d4d21880589b, content=偏重的研究方向：生物信息 经验分享：有点无语，投的生信以没有做验证为理由拒稿，然而无论是标题还是摘要都着重写了验证部分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a38173164, createdName=ms7000001263360888, createdTime=Sun Feb 18 22:49:56 CST 2024, time=2024-02-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187197, encodeId=70ea218e19781, content=一般几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Feb 13 22:26:33 CST 2024, time=2024-02-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2129635, encodeId=778f212963576, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度还可以，没有那么慢。 2.4，投稿 2.17, 送外审 3.28，大修 4.7，修回 4.26，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0de2443241, createdName=然、, createdTime=Tue May 02 02:14:34 CST 2023, time=2023-05-02, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=909655, encodeId=fe449096558c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：基因 经验分享：刚发表了一篇，我也来分享一下：纯生信分析文章，Received 28 July 2020; Received in revised form 1 November 2020; Accepted 1 December 2020；Available online 14 December 2020。审稿偏慢，一审3个月，小修，很快接收，订阅模式不需要版面费，这一点非常好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32432154011, createdName=137EoZs9227, createdTime=Sun Dec 20 22:23:33 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156687, encodeId=2582215668e2e, content=接收之后多久发proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Fri Sep 08 11:03:12 CST 2023, time=2023-09-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1068815, encodeId=a3b61068815a7, content=请问大家推荐审稿人怎么填的，还有通讯作者我咋改不了了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c8f2b10a854a89661cdd74b28f3aab31/5ce6cf574e5eba0e8ed4f71f7dcc1d37.jpg, createdBy=23695158969, createdName=146b113dm12(暂无昵称), createdTime=Wed Nov 10 00:14:59 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239026, encodeId=f721123902632, content=审稿速度:6.0 偏重的研究方向：遗传 经验分享：10.14投稿 10.18Associate Editor 10.29Editor in cheif under review 12.7修稿意见 12.24修后重投 1.15Editor in cheif under review 1.19修稿意见 2.16修后重投 2.25小修意见 2.28修回 3.4接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a66a5585339, createdName=一把辛酸泪, createdTime=Tue Aug 16 14:46:10 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586729, encodeId=5430586e294a, content=纯生信分析，没做基础实验验证，有可能收吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/01/253ec4d94f720dd8d7ff9fd9eee11139.jpg, createdBy=75232378321, createdName=烽火很忙, createdTime=Mon Mar 16 00:00:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228064, encodeId=08051228064f1, content=偏重的研究方向：分子生物学 经验分享：好垃圾的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0f35577132, createdName=机智二次元, createdTime=Wed Jun 22 20:27:06 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237318, encodeId=eca9123e3183d, content=虽说是一个老牌的期刊，但是找的审稿人非常不专业。 我投的方向是纯基础研究，内容是XBP1s对增殖及成骨相关的调控作用。送审以后一个月返回意见，一共两个审稿人，其中第一个（感觉是非英语国家的人）首先质疑了我qPCR的扩增效率，然后让我提供提取的RNA的浓度；还提了一个问题是“明明那么多促进增殖和成骨的基因，为什么作者一定要聚焦于XBP1s”，我真的是气不打一处来，introduction和亮点明明写得很清楚，我就是研究ERS通路的你问我为啥要研究这个？那我问你为啥要每天吃饭你怎么说？ 明明都是用试剂盒提取的流程化的东西非要质疑一遍，我就又给他跑了一边RNA电泳，一共十几个问题我都给他加了数据图，并且补了染色实验，疫情封控下还忙活了一个多月，补的实验数据几乎是原稿的一倍，都够再写一篇的了，结果返回去不到一天就光速审完，一周后编辑拒稿，也没有具体理由，也没有拒稿意见。找的这个审稿人真的恶心到我了，也不说文章缺陷在哪里，就是为了拒稿而拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56466500170, createdName=ms5000001139229179, createdTime=Mon Aug 08 12:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2023-05-02 然、来自辽宁省

审稿速度:3.0 | 投稿命中率:50.0
经验分享：速度还可以，没有那么慢。
2.4，投稿
2.17, 送外审
3.28，大修
4.7，修回
4.26，接受

56 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2188058, encodeId=7d4d21880589b, content=偏重的研究方向：生物信息 经验分享：有点无语，投的生信以没有做验证为理由拒稿，然而无论是标题还是摘要都着重写了验证部分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a38173164, createdName=ms7000001263360888, createdTime=Sun Feb 18 22:49:56 CST 2024, time=2024-02-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187197, encodeId=70ea218e19781, content=一般几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Feb 13 22:26:33 CST 2024, time=2024-02-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2129635, encodeId=778f212963576, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度还可以，没有那么慢。 2.4，投稿 2.17, 送外审 3.28，大修 4.7，修回 4.26，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0de2443241, createdName=然、, createdTime=Tue May 02 02:14:34 CST 2023, time=2023-05-02, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=909655, encodeId=fe449096558c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：基因 经验分享：刚发表了一篇，我也来分享一下：纯生信分析文章，Received 28 July 2020; Received in revised form 1 November 2020; Accepted 1 December 2020；Available online 14 December 2020。审稿偏慢，一审3个月，小修，很快接收，订阅模式不需要版面费，这一点非常好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32432154011, createdName=137EoZs9227, createdTime=Sun Dec 20 22:23:33 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156687, encodeId=2582215668e2e, content=接收之后多久发proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Fri Sep 08 11:03:12 CST 2023, time=2023-09-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1068815, encodeId=a3b61068815a7, content=请问大家推荐审稿人怎么填的，还有通讯作者我咋改不了了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c8f2b10a854a89661cdd74b28f3aab31/5ce6cf574e5eba0e8ed4f71f7dcc1d37.jpg, createdBy=23695158969, createdName=146b113dm12(暂无昵称), createdTime=Wed Nov 10 00:14:59 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239026, encodeId=f721123902632, content=审稿速度:6.0 偏重的研究方向：遗传 经验分享：10.14投稿 10.18Associate Editor 10.29Editor in cheif under review 12.7修稿意见 12.24修后重投 1.15Editor in cheif under review 1.19修稿意见 2.16修后重投 2.25小修意见 2.28修回 3.4接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a66a5585339, createdName=一把辛酸泪, createdTime=Tue Aug 16 14:46:10 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586729, encodeId=5430586e294a, content=纯生信分析，没做基础实验验证，有可能收吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/01/253ec4d94f720dd8d7ff9fd9eee11139.jpg, createdBy=75232378321, createdName=烽火很忙, createdTime=Mon Mar 16 00:00:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228064, encodeId=08051228064f1, content=偏重的研究方向：分子生物学 经验分享：好垃圾的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0f35577132, createdName=机智二次元, createdTime=Wed Jun 22 20:27:06 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237318, encodeId=eca9123e3183d, content=虽说是一个老牌的期刊，但是找的审稿人非常不专业。 我投的方向是纯基础研究，内容是XBP1s对增殖及成骨相关的调控作用。送审以后一个月返回意见，一共两个审稿人，其中第一个（感觉是非英语国家的人）首先质疑了我qPCR的扩增效率，然后让我提供提取的RNA的浓度；还提了一个问题是“明明那么多促进增殖和成骨的基因，为什么作者一定要聚焦于XBP1s”，我真的是气不打一处来，introduction和亮点明明写得很清楚，我就是研究ERS通路的你问我为啥要研究这个？那我问你为啥要每天吃饭你怎么说？ 明明都是用试剂盒提取的流程化的东西非要质疑一遍，我就又给他跑了一边RNA电泳，一共十几个问题我都给他加了数据图，并且补了染色实验，疫情封控下还忙活了一个多月，补的实验数据几乎是原稿的一倍，都够再写一篇的了，结果返回去不到一天就光速审完，一周后编辑拒稿，也没有具体理由，也没有拒稿意见。找的这个审稿人真的恶心到我了，也不说文章缺陷在哪里，就是为了拒稿而拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56466500170, createdName=ms5000001139229179, createdTime=Mon Aug 08 12:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2020-12-20 137EoZs9227

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：基因
经验分享：刚发表了一篇，我也来分享一下：纯生信分析文章，Received 28 July 2020; Received in revised form 1 November 2020; Accepted 1 December 2020；Available online 14 December 2020。审稿偏慢，一审3个月，小修，很快接收，订阅模式不需要版面费，这一点非常好。

173 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2188058, encodeId=7d4d21880589b, content=偏重的研究方向：生物信息 经验分享：有点无语，投的生信以没有做验证为理由拒稿，然而无论是标题还是摘要都着重写了验证部分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a38173164, createdName=ms7000001263360888, createdTime=Sun Feb 18 22:49:56 CST 2024, time=2024-02-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187197, encodeId=70ea218e19781, content=一般几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Feb 13 22:26:33 CST 2024, time=2024-02-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2129635, encodeId=778f212963576, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度还可以，没有那么慢。 2.4，投稿 2.17, 送外审 3.28，大修 4.7，修回 4.26，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0de2443241, createdName=然、, createdTime=Tue May 02 02:14:34 CST 2023, time=2023-05-02, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=909655, encodeId=fe449096558c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：基因 经验分享：刚发表了一篇，我也来分享一下：纯生信分析文章，Received 28 July 2020; Received in revised form 1 November 2020; Accepted 1 December 2020；Available online 14 December 2020。审稿偏慢，一审3个月，小修，很快接收，订阅模式不需要版面费，这一点非常好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32432154011, createdName=137EoZs9227, createdTime=Sun Dec 20 22:23:33 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156687, encodeId=2582215668e2e, content=接收之后多久发proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Fri Sep 08 11:03:12 CST 2023, time=2023-09-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1068815, encodeId=a3b61068815a7, content=请问大家推荐审稿人怎么填的，还有通讯作者我咋改不了了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c8f2b10a854a89661cdd74b28f3aab31/5ce6cf574e5eba0e8ed4f71f7dcc1d37.jpg, createdBy=23695158969, createdName=146b113dm12(暂无昵称), createdTime=Wed Nov 10 00:14:59 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239026, encodeId=f721123902632, content=审稿速度:6.0 偏重的研究方向：遗传 经验分享：10.14投稿 10.18Associate Editor 10.29Editor in cheif under review 12.7修稿意见 12.24修后重投 1.15Editor in cheif under review 1.19修稿意见 2.16修后重投 2.25小修意见 2.28修回 3.4接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a66a5585339, createdName=一把辛酸泪, createdTime=Tue Aug 16 14:46:10 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586729, encodeId=5430586e294a, content=纯生信分析，没做基础实验验证，有可能收吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/01/253ec4d94f720dd8d7ff9fd9eee11139.jpg, createdBy=75232378321, createdName=烽火很忙, createdTime=Mon Mar 16 00:00:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228064, encodeId=08051228064f1, content=偏重的研究方向：分子生物学 经验分享：好垃圾的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0f35577132, createdName=机智二次元, createdTime=Wed Jun 22 20:27:06 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237318, encodeId=eca9123e3183d, content=虽说是一个老牌的期刊，但是找的审稿人非常不专业。 我投的方向是纯基础研究，内容是XBP1s对增殖及成骨相关的调控作用。送审以后一个月返回意见，一共两个审稿人，其中第一个（感觉是非英语国家的人）首先质疑了我qPCR的扩增效率，然后让我提供提取的RNA的浓度；还提了一个问题是“明明那么多促进增殖和成骨的基因，为什么作者一定要聚焦于XBP1s”，我真的是气不打一处来，introduction和亮点明明写得很清楚，我就是研究ERS通路的你问我为啥要研究这个？那我问你为啥要每天吃饭你怎么说？ 明明都是用试剂盒提取的流程化的东西非要质疑一遍，我就又给他跑了一边RNA电泳，一共十几个问题我都给他加了数据图，并且补了染色实验，疫情封控下还忙活了一个多月，补的实验数据几乎是原稿的一倍，都够再写一篇的了，结果返回去不到一天就光速审完，一周后编辑拒稿，也没有具体理由，也没有拒稿意见。找的这个审稿人真的恶心到我了，也不说文章缺陷在哪里，就是为了拒稿而拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56466500170, createdName=ms5000001139229179, createdTime=Mon Aug 08 12:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2023-09-08 MedSci_007 来自吉林省

接收之后多久发proof呀？

40 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2188058, encodeId=7d4d21880589b, content=偏重的研究方向：生物信息 经验分享：有点无语，投的生信以没有做验证为理由拒稿，然而无论是标题还是摘要都着重写了验证部分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a38173164, createdName=ms7000001263360888, createdTime=Sun Feb 18 22:49:56 CST 2024, time=2024-02-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187197, encodeId=70ea218e19781, content=一般几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Feb 13 22:26:33 CST 2024, time=2024-02-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2129635, encodeId=778f212963576, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度还可以，没有那么慢。 2.4，投稿 2.17, 送外审 3.28，大修 4.7，修回 4.26，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0de2443241, createdName=然、, createdTime=Tue May 02 02:14:34 CST 2023, time=2023-05-02, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=909655, encodeId=fe449096558c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：基因 经验分享：刚发表了一篇，我也来分享一下：纯生信分析文章，Received 28 July 2020; Received in revised form 1 November 2020; Accepted 1 December 2020；Available online 14 December 2020。审稿偏慢，一审3个月，小修，很快接收，订阅模式不需要版面费，这一点非常好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32432154011, createdName=137EoZs9227, createdTime=Sun Dec 20 22:23:33 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156687, encodeId=2582215668e2e, content=接收之后多久发proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Fri Sep 08 11:03:12 CST 2023, time=2023-09-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1068815, encodeId=a3b61068815a7, content=请问大家推荐审稿人怎么填的，还有通讯作者我咋改不了了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c8f2b10a854a89661cdd74b28f3aab31/5ce6cf574e5eba0e8ed4f71f7dcc1d37.jpg, createdBy=23695158969, createdName=146b113dm12(暂无昵称), createdTime=Wed Nov 10 00:14:59 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239026, encodeId=f721123902632, content=审稿速度:6.0 偏重的研究方向：遗传 经验分享：10.14投稿 10.18Associate Editor 10.29Editor in cheif under review 12.7修稿意见 12.24修后重投 1.15Editor in cheif under review 1.19修稿意见 2.16修后重投 2.25小修意见 2.28修回 3.4接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a66a5585339, createdName=一把辛酸泪, createdTime=Tue Aug 16 14:46:10 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586729, encodeId=5430586e294a, content=纯生信分析，没做基础实验验证，有可能收吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/01/253ec4d94f720dd8d7ff9fd9eee11139.jpg, createdBy=75232378321, createdName=烽火很忙, createdTime=Mon Mar 16 00:00:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228064, encodeId=08051228064f1, content=偏重的研究方向：分子生物学 经验分享：好垃圾的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0f35577132, createdName=机智二次元, createdTime=Wed Jun 22 20:27:06 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237318, encodeId=eca9123e3183d, content=虽说是一个老牌的期刊，但是找的审稿人非常不专业。 我投的方向是纯基础研究，内容是XBP1s对增殖及成骨相关的调控作用。送审以后一个月返回意见，一共两个审稿人，其中第一个（感觉是非英语国家的人）首先质疑了我qPCR的扩增效率，然后让我提供提取的RNA的浓度；还提了一个问题是“明明那么多促进增殖和成骨的基因，为什么作者一定要聚焦于XBP1s”，我真的是气不打一处来，introduction和亮点明明写得很清楚，我就是研究ERS通路的你问我为啥要研究这个？那我问你为啥要每天吃饭你怎么说？ 明明都是用试剂盒提取的流程化的东西非要质疑一遍，我就又给他跑了一边RNA电泳，一共十几个问题我都给他加了数据图，并且补了染色实验，疫情封控下还忙活了一个多月，补的实验数据几乎是原稿的一倍，都够再写一篇的了，结果返回去不到一天就光速审完，一周后编辑拒稿，也没有具体理由，也没有拒稿意见。找的这个审稿人真的恶心到我了，也不说文章缺陷在哪里，就是为了拒稿而拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56466500170, createdName=ms5000001139229179, createdTime=Mon Aug 08 12:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2021-11-10 146b113dm12(暂无昵称)

请问大家推荐审稿人怎么填的，还有通讯作者我咋改不了了

94 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2188058, encodeId=7d4d21880589b, content=偏重的研究方向：生物信息 经验分享：有点无语，投的生信以没有做验证为理由拒稿，然而无论是标题还是摘要都着重写了验证部分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a38173164, createdName=ms7000001263360888, createdTime=Sun Feb 18 22:49:56 CST 2024, time=2024-02-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187197, encodeId=70ea218e19781, content=一般几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Feb 13 22:26:33 CST 2024, time=2024-02-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2129635, encodeId=778f212963576, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度还可以，没有那么慢。 2.4，投稿 2.17, 送外审 3.28，大修 4.7，修回 4.26，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0de2443241, createdName=然、, createdTime=Tue May 02 02:14:34 CST 2023, time=2023-05-02, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=909655, encodeId=fe449096558c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：基因 经验分享：刚发表了一篇，我也来分享一下：纯生信分析文章，Received 28 July 2020; Received in revised form 1 November 2020; Accepted 1 December 2020；Available online 14 December 2020。审稿偏慢，一审3个月，小修，很快接收，订阅模式不需要版面费，这一点非常好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32432154011, createdName=137EoZs9227, createdTime=Sun Dec 20 22:23:33 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156687, encodeId=2582215668e2e, content=接收之后多久发proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Fri Sep 08 11:03:12 CST 2023, time=2023-09-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1068815, encodeId=a3b61068815a7, content=请问大家推荐审稿人怎么填的，还有通讯作者我咋改不了了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c8f2b10a854a89661cdd74b28f3aab31/5ce6cf574e5eba0e8ed4f71f7dcc1d37.jpg, createdBy=23695158969, createdName=146b113dm12(暂无昵称), createdTime=Wed Nov 10 00:14:59 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239026, encodeId=f721123902632, content=审稿速度:6.0 偏重的研究方向：遗传 经验分享：10.14投稿 10.18Associate Editor 10.29Editor in cheif under review 12.7修稿意见 12.24修后重投 1.15Editor in cheif under review 1.19修稿意见 2.16修后重投 2.25小修意见 2.28修回 3.4接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a66a5585339, createdName=一把辛酸泪, createdTime=Tue Aug 16 14:46:10 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586729, encodeId=5430586e294a, content=纯生信分析，没做基础实验验证，有可能收吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/01/253ec4d94f720dd8d7ff9fd9eee11139.jpg, createdBy=75232378321, createdName=烽火很忙, createdTime=Mon Mar 16 00:00:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228064, encodeId=08051228064f1, content=偏重的研究方向：分子生物学 经验分享：好垃圾的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0f35577132, createdName=机智二次元, createdTime=Wed Jun 22 20:27:06 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237318, encodeId=eca9123e3183d, content=虽说是一个老牌的期刊，但是找的审稿人非常不专业。 我投的方向是纯基础研究，内容是XBP1s对增殖及成骨相关的调控作用。送审以后一个月返回意见，一共两个审稿人，其中第一个（感觉是非英语国家的人）首先质疑了我qPCR的扩增效率，然后让我提供提取的RNA的浓度；还提了一个问题是“明明那么多促进增殖和成骨的基因，为什么作者一定要聚焦于XBP1s”，我真的是气不打一处来，introduction和亮点明明写得很清楚，我就是研究ERS通路的你问我为啥要研究这个？那我问你为啥要每天吃饭你怎么说？ 明明都是用试剂盒提取的流程化的东西非要质疑一遍，我就又给他跑了一边RNA电泳，一共十几个问题我都给他加了数据图，并且补了染色实验，疫情封控下还忙活了一个多月，补的实验数据几乎是原稿的一倍，都够再写一篇的了，结果返回去不到一天就光速审完，一周后编辑拒稿，也没有具体理由，也没有拒稿意见。找的这个审稿人真的恶心到我了，也不说文章缺陷在哪里，就是为了拒稿而拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56466500170, createdName=ms5000001139229179, createdTime=Mon Aug 08 12:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2022-08-16 一把辛酸泪

审稿速度:6.0
偏重的研究方向：遗传
经验分享：10.14投稿
10.18Associate Editor
10.29Editor in cheif
under review
12.7修稿意见
12.24修后重投
1.15Editor in cheif
under review
1.19修稿意见
2.16修后重投
2.25小修意见
2.28修回
3.4接收

38 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2188058, encodeId=7d4d21880589b, content=偏重的研究方向：生物信息 经验分享：有点无语，投的生信以没有做验证为理由拒稿，然而无论是标题还是摘要都着重写了验证部分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a38173164, createdName=ms7000001263360888, createdTime=Sun Feb 18 22:49:56 CST 2024, time=2024-02-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187197, encodeId=70ea218e19781, content=一般几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Feb 13 22:26:33 CST 2024, time=2024-02-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2129635, encodeId=778f212963576, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度还可以，没有那么慢。 2.4，投稿 2.17, 送外审 3.28，大修 4.7，修回 4.26，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0de2443241, createdName=然、, createdTime=Tue May 02 02:14:34 CST 2023, time=2023-05-02, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=909655, encodeId=fe449096558c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：基因 经验分享：刚发表了一篇，我也来分享一下：纯生信分析文章，Received 28 July 2020; Received in revised form 1 November 2020; Accepted 1 December 2020；Available online 14 December 2020。审稿偏慢，一审3个月，小修，很快接收，订阅模式不需要版面费，这一点非常好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32432154011, createdName=137EoZs9227, createdTime=Sun Dec 20 22:23:33 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156687, encodeId=2582215668e2e, content=接收之后多久发proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Fri Sep 08 11:03:12 CST 2023, time=2023-09-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1068815, encodeId=a3b61068815a7, content=请问大家推荐审稿人怎么填的，还有通讯作者我咋改不了了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c8f2b10a854a89661cdd74b28f3aab31/5ce6cf574e5eba0e8ed4f71f7dcc1d37.jpg, createdBy=23695158969, createdName=146b113dm12(暂无昵称), createdTime=Wed Nov 10 00:14:59 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239026, encodeId=f721123902632, content=审稿速度:6.0 偏重的研究方向：遗传 经验分享：10.14投稿 10.18Associate Editor 10.29Editor in cheif under review 12.7修稿意见 12.24修后重投 1.15Editor in cheif under review 1.19修稿意见 2.16修后重投 2.25小修意见 2.28修回 3.4接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a66a5585339, createdName=一把辛酸泪, createdTime=Tue Aug 16 14:46:10 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586729, encodeId=5430586e294a, content=纯生信分析，没做基础实验验证，有可能收吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/01/253ec4d94f720dd8d7ff9fd9eee11139.jpg, createdBy=75232378321, createdName=烽火很忙, createdTime=Mon Mar 16 00:00:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228064, encodeId=08051228064f1, content=偏重的研究方向：分子生物学 经验分享：好垃圾的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0f35577132, createdName=机智二次元, createdTime=Wed Jun 22 20:27:06 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237318, encodeId=eca9123e3183d, content=虽说是一个老牌的期刊，但是找的审稿人非常不专业。 我投的方向是纯基础研究，内容是XBP1s对增殖及成骨相关的调控作用。送审以后一个月返回意见，一共两个审稿人，其中第一个（感觉是非英语国家的人）首先质疑了我qPCR的扩增效率，然后让我提供提取的RNA的浓度；还提了一个问题是“明明那么多促进增殖和成骨的基因，为什么作者一定要聚焦于XBP1s”，我真的是气不打一处来，introduction和亮点明明写得很清楚，我就是研究ERS通路的你问我为啥要研究这个？那我问你为啥要每天吃饭你怎么说？ 明明都是用试剂盒提取的流程化的东西非要质疑一遍，我就又给他跑了一边RNA电泳，一共十几个问题我都给他加了数据图，并且补了染色实验，疫情封控下还忙活了一个多月，补的实验数据几乎是原稿的一倍，都够再写一篇的了，结果返回去不到一天就光速审完，一周后编辑拒稿，也没有具体理由，也没有拒稿意见。找的这个审稿人真的恶心到我了，也不说文章缺陷在哪里，就是为了拒稿而拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56466500170, createdName=ms5000001139229179, createdTime=Mon Aug 08 12:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2020-03-16 烽火很忙

纯生信分析，没做基础实验验证，有可能收吗?

254 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2188058, encodeId=7d4d21880589b, content=偏重的研究方向：生物信息 经验分享：有点无语，投的生信以没有做验证为理由拒稿，然而无论是标题还是摘要都着重写了验证部分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a38173164, createdName=ms7000001263360888, createdTime=Sun Feb 18 22:49:56 CST 2024, time=2024-02-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187197, encodeId=70ea218e19781, content=一般几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Feb 13 22:26:33 CST 2024, time=2024-02-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2129635, encodeId=778f212963576, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度还可以，没有那么慢。 2.4，投稿 2.17, 送外审 3.28，大修 4.7，修回 4.26，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0de2443241, createdName=然、, createdTime=Tue May 02 02:14:34 CST 2023, time=2023-05-02, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=909655, encodeId=fe449096558c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：基因 经验分享：刚发表了一篇，我也来分享一下：纯生信分析文章，Received 28 July 2020; Received in revised form 1 November 2020; Accepted 1 December 2020；Available online 14 December 2020。审稿偏慢，一审3个月，小修，很快接收，订阅模式不需要版面费，这一点非常好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32432154011, createdName=137EoZs9227, createdTime=Sun Dec 20 22:23:33 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156687, encodeId=2582215668e2e, content=接收之后多久发proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Fri Sep 08 11:03:12 CST 2023, time=2023-09-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1068815, encodeId=a3b61068815a7, content=请问大家推荐审稿人怎么填的，还有通讯作者我咋改不了了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c8f2b10a854a89661cdd74b28f3aab31/5ce6cf574e5eba0e8ed4f71f7dcc1d37.jpg, createdBy=23695158969, createdName=146b113dm12(暂无昵称), createdTime=Wed Nov 10 00:14:59 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239026, encodeId=f721123902632, content=审稿速度:6.0 偏重的研究方向：遗传 经验分享：10.14投稿 10.18Associate Editor 10.29Editor in cheif under review 12.7修稿意见 12.24修后重投 1.15Editor in cheif under review 1.19修稿意见 2.16修后重投 2.25小修意见 2.28修回 3.4接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a66a5585339, createdName=一把辛酸泪, createdTime=Tue Aug 16 14:46:10 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586729, encodeId=5430586e294a, content=纯生信分析，没做基础实验验证，有可能收吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/01/253ec4d94f720dd8d7ff9fd9eee11139.jpg, createdBy=75232378321, createdName=烽火很忙, createdTime=Mon Mar 16 00:00:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228064, encodeId=08051228064f1, content=偏重的研究方向：分子生物学 经验分享：好垃圾的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0f35577132, createdName=机智二次元, createdTime=Wed Jun 22 20:27:06 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237318, encodeId=eca9123e3183d, content=虽说是一个老牌的期刊，但是找的审稿人非常不专业。 我投的方向是纯基础研究，内容是XBP1s对增殖及成骨相关的调控作用。送审以后一个月返回意见，一共两个审稿人，其中第一个（感觉是非英语国家的人）首先质疑了我qPCR的扩增效率，然后让我提供提取的RNA的浓度；还提了一个问题是“明明那么多促进增殖和成骨的基因，为什么作者一定要聚焦于XBP1s”，我真的是气不打一处来，introduction和亮点明明写得很清楚，我就是研究ERS通路的你问我为啥要研究这个？那我问你为啥要每天吃饭你怎么说？ 明明都是用试剂盒提取的流程化的东西非要质疑一遍，我就又给他跑了一边RNA电泳，一共十几个问题我都给他加了数据图，并且补了染色实验，疫情封控下还忙活了一个多月，补的实验数据几乎是原稿的一倍，都够再写一篇的了，结果返回去不到一天就光速审完，一周后编辑拒稿，也没有具体理由，也没有拒稿意见。找的这个审稿人真的恶心到我了，也不说文章缺陷在哪里，就是为了拒稿而拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56466500170, createdName=ms5000001139229179, createdTime=Mon Aug 08 12:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2022-06-22 机智二次元

偏重的研究方向：分子生物学
经验分享：好垃圾的期刊

42 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2188058, encodeId=7d4d21880589b, content=偏重的研究方向：生物信息 经验分享：有点无语，投的生信以没有做验证为理由拒稿，然而无论是标题还是摘要都着重写了验证部分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a38173164, createdName=ms7000001263360888, createdTime=Sun Feb 18 22:49:56 CST 2024, time=2024-02-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187197, encodeId=70ea218e19781, content=一般几个审稿人？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Feb 13 22:26:33 CST 2024, time=2024-02-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2129635, encodeId=778f212963576, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度还可以，没有那么慢。 2.4，投稿 2.17, 送外审 3.28，大修 4.7，修回 4.26，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0de2443241, createdName=然、, createdTime=Tue May 02 02:14:34 CST 2023, time=2023-05-02, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=909655, encodeId=fe449096558c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：基因 经验分享：刚发表了一篇，我也来分享一下：纯生信分析文章，Received 28 July 2020; Received in revised form 1 November 2020; Accepted 1 December 2020；Available online 14 December 2020。审稿偏慢，一审3个月，小修，很快接收，订阅模式不需要版面费，这一点非常好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32432154011, createdName=137EoZs9227, createdTime=Sun Dec 20 22:23:33 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156687, encodeId=2582215668e2e, content=接收之后多久发proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230102/946f899161a14c3dbe77c26d05ba17d8/114975187bd54951beda40eaafd6f34e.jpg, createdBy=59ae5404963, createdName=MedSci_007, createdTime=Fri Sep 08 11:03:12 CST 2023, time=2023-09-08, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=1068815, encodeId=a3b61068815a7, content=请问大家推荐审稿人怎么填的，还有通讯作者我咋改不了了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c8f2b10a854a89661cdd74b28f3aab31/5ce6cf574e5eba0e8ed4f71f7dcc1d37.jpg, createdBy=23695158969, createdName=146b113dm12(暂无昵称), createdTime=Wed Nov 10 00:14:59 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239026, encodeId=f721123902632, content=审稿速度:6.0 偏重的研究方向：遗传 经验分享：10.14投稿 10.18Associate Editor 10.29Editor in cheif under review 12.7修稿意见 12.24修后重投 1.15Editor in cheif under review 1.19修稿意见 2.16修后重投 2.25小修意见 2.28修回 3.4接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a66a5585339, createdName=一把辛酸泪, createdTime=Tue Aug 16 14:46:10 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586729, encodeId=5430586e294a, content=纯生信分析，没做基础实验验证，有可能收吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/01/253ec4d94f720dd8d7ff9fd9eee11139.jpg, createdBy=75232378321, createdName=烽火很忙, createdTime=Mon Mar 16 00:00:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228064, encodeId=08051228064f1, content=偏重的研究方向：分子生物学 经验分享：好垃圾的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0f35577132, createdName=机智二次元, createdTime=Wed Jun 22 20:27:06 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237318, encodeId=eca9123e3183d, content=虽说是一个老牌的期刊，但是找的审稿人非常不专业。 我投的方向是纯基础研究，内容是XBP1s对增殖及成骨相关的调控作用。送审以后一个月返回意见，一共两个审稿人，其中第一个（感觉是非英语国家的人）首先质疑了我qPCR的扩增效率，然后让我提供提取的RNA的浓度；还提了一个问题是“明明那么多促进增殖和成骨的基因，为什么作者一定要聚焦于XBP1s”，我真的是气不打一处来，introduction和亮点明明写得很清楚，我就是研究ERS通路的你问我为啥要研究这个？那我问你为啥要每天吃饭你怎么说？ 明明都是用试剂盒提取的流程化的东西非要质疑一遍，我就又给他跑了一边RNA电泳，一共十几个问题我都给他加了数据图，并且补了染色实验，疫情封控下还忙活了一个多月，补的实验数据几乎是原稿的一倍，都够再写一篇的了，结果返回去不到一天就光速审完，一周后编辑拒稿，也没有具体理由，也没有拒稿意见。找的这个审稿人真的恶心到我了，也不说文章缺陷在哪里，就是为了拒稿而拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56466500170, createdName=ms5000001139229179, createdTime=Mon Aug 08 12:40:02 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2022-08-08 ms5000001139229179

虽说是一个老牌的期刊，但是找的审稿人非常不专业。
我投的方向是纯基础研究，内容是XBP1s对增殖及成骨相关的调控作用。送审以后一个月返回意见，一共两个审稿人，其中第一个（感觉是非英语国家的人）首先质疑了我qPCR的扩增效率，然后让我提供提取的RNA的浓度；还提了一个问题是“明明那么多促进增殖和成骨的基因，为什么作者一定要聚焦于XBP1s”，我真的是气不打一处来，introduction和亮点明明写得很清楚，我就是研究ERS通路的你问我为啥要研究这个？那我问你为啥要每天吃饭你怎么说？
明明都是用试剂盒提取的流程化的东西非要质疑一遍，我就又给他跑了一边RNA电泳，一共十几个问题我都给他加了数据图，并且补了染色实验，疫情封控下还忙活了一个多月，补的实验数据几乎是原稿的一倍，都够再写一篇的了，结果返回去不到一天就光速审完，一周后编辑拒稿，也没有具体理由，也没有拒稿意见。找的这个审稿人真的恶心到我了，也不说文章缺陷在哪里，就是为了拒稿而拒稿。

47 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务